CN112137935A - 一种组合物及其用途 - Google Patents
一种组合物及其用途 Download PDFInfo
- Publication number
- CN112137935A CN112137935A CN202011159114.2A CN202011159114A CN112137935A CN 112137935 A CN112137935 A CN 112137935A CN 202011159114 A CN202011159114 A CN 202011159114A CN 112137935 A CN112137935 A CN 112137935A
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- cannabis
- hemp
- artemisia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 52
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 32
- 240000000011 Artemisia annua Species 0.000 claims abstract description 32
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 28
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 24
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 24
- 235000009120 camo Nutrition 0.000 claims abstract description 24
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 24
- 239000011487 hemp Substances 0.000 claims abstract description 24
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- 206010000496 acne Diseases 0.000 claims abstract description 4
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 4
- 206010015150 Erythema Diseases 0.000 claims abstract description 3
- 230000000172 allergic effect Effects 0.000 claims abstract description 3
- 231100000321 erythema Toxicity 0.000 claims abstract description 3
- 241000218236 Cannabis Species 0.000 claims description 27
- 241000049464 Artemisia apiacea Species 0.000 claims description 18
- 235000011570 Artemisia caruifolia var apiacea Nutrition 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 13
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 12
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims description 12
- 229960004191 artemisinin Drugs 0.000 claims description 12
- 229930101531 artemisinin Natural products 0.000 claims description 12
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical group OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 12
- 229950011318 cannabidiol Drugs 0.000 claims description 12
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 12
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 230000003064 anti-oxidating effect Effects 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 230000037072 sun protection Effects 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 abstract description 4
- 229940119569 wormwood extract Drugs 0.000 abstract description 4
- 230000004888 barrier function Effects 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 230000003078 antioxidant effect Effects 0.000 description 14
- 239000000516 sunscreening agent Substances 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000000475 sunscreen effect Effects 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 235000008697 Cannabis sativa Nutrition 0.000 description 4
- -1 aqua Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010036087 Polymorphic light eruption Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000005455 negative regulation of mast cell degranulation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请公开了一种组合物,其特征在于,所述组合物包括大麻提取物和青蒿提取物,所述大麻提取物和青蒿提取物的比例为10:1至1:10。本申请还公开了所述组合物在在制备护肤品或药品中的用途,所述护肤品或药品用于痤疮、炎症反应和/或过敏性红斑、抗菌。
Description
技术领域
本发明涉及生物医药领域,尤其涉及一种大麻青蒿组合物及其用途。
背景技术
皮肤是人体面积最大的组织,位于体表最外层,具有屏障、吸收、分泌、排泄、代谢、免疫、体温调节及感觉功能。其中,皮肤屏障是基础功能,包括表皮渗透屏障、免疫屏障、色素屏障等,同时,皮肤微生态及酸性环境与皮肤屏障之间也有着千丝万缕的联系,共同维持皮肤正常生理代谢。
表皮渗透屏障功能,对外可以抵御抗原物质、微生物、日光等的侵袭,对内可防止体内营养物质、水分的丢失。表皮渗透屏障受损,经表皮水分流失(transepidermalwaterloss,TEWL)增加,皮肤则出现干燥、脱屑。同时,对外界抗原及微生物的抵御能力下降,可导致多种皮肤病的发生。表皮渗透屏障与免疫屏障、酸性屏障及微生态共同构成一个整体防御系统,表皮微生态、pH值可影响表皮渗透屏障,表皮渗透屏障受损,又可影响其他屏障功能。
表皮渗透屏障受多种因素影响,如年龄等内在因素,以及紫外线等外在因素。表皮渗透屏障受损,老年人容易出现瘙痒、皮肤炎症反应,婴幼儿易患有特应性皮炎。紫外线是影响表皮渗透屏障的主要外在因素。当前诸多研究显示特应性皮炎、多形性日光疹、痤疮、玫瑰痤疮、湿疹、光老化等皮肤病的发生都与表皮渗透屏障受损有关,提示临床治疗这类皮肤病时需注意修复受损的表皮渗透屏障功能。
目前临床上常用的医疗美容技术,如:激光、光电技术、纳米微晶技术、光动力、医学护肤品等对皮肤屏障功能进行修复。其中护肤品因使用方便,接受度最高。因此,本领域的技术人员致力于开发一种保护皮肤并能够修复受损皮肤屏障功能的护肤品。
发明内容
为实现上述目的,本申请提供了一种组合物,其特征在于,其包括大麻提取物和青蒿提取物,所述大麻提取物和青蒿提取物的比例为10:1至1:10。
在某些实施方式中,所述组合物具有至少如下功能之一:
a)抗氧化作用;
b)防御UVA和/或UVB对皮肤的损害;
c)缓解炎症反应或过敏反应;
d)抑制细菌生长。
在某些实施方式中,所述大麻提取物来自大麻花叶、大麻果仁、大麻籽油和/或大麻槿茎粉。
在某些实施方式中,所述青蒿提取物来自青蒿叶。
在某些实施方式中,所述大麻提取物为大麻二酚。
在某些实施方式中,所述大麻二酚的纯度不低于95%(质量比)。
在某些实施方式中,所述青蒿提取物为青蒿素。
在某些实施方式中,所述青蒿素的纯度不低于95%(质量比)。
在某些实施方式中,所述大麻提取物的制备方法为:选取9-10月大麻花叶,制成干制品,取所述干制品加入10倍重量的95%的乙醇,超声提取,分离提取液,真空浓缩干燥。
在某些实施方式中,所述青蒿提取物的制备方法为:选取9-10月青蒿叶,制成干制品,取所述干制品加入10倍重量的95%的乙醇,超声提取分离提取液,真空浓缩干燥。
在某些实施方式中,所述大麻提取物和青蒿提取物的比例为10:1。
在某些实施方式中,所述大麻提取物和青蒿提取物的比例为5:1。
在某些实施方式中,所述大麻提取物和青蒿提取物的比例为1:1。
在某些实施方式中,所述大麻提取物和青蒿提取物的比例为1:5。
在某些实施方式中,所述大麻提取物和青蒿提取物的比例为1:10。
在某些实施方式中,所述组合物的制备方法为:a)将大麻果实和青蒿叶片1:1混合,蒸馏法制备挥发油;或者,b)大麻叶片和青蒿叶片2:1混合,40℃-50℃干燥,超微粉碎后过300目筛。
另一方面,本申请还提供本申请所述的组合物在制备护肤品或药品中的用途,所述护肤品或药品用于防晒、预防、缓解或治疗痤疮、炎症反应和/或过敏性红斑、抗菌。
在某些实施方式中,所述护肤品或药品被配置为经皮肤施用。
在某些实施方式中,所述护肤品或药品包括合适的辅料。
在某些实施方式中,所述护肤品或药品包括合适的辅料。
在某些实施方式中,所述护肤品或药品中所述组合物的质量分数为0.5%至10%。
在某些实施方式中,所述护肤品或药品被配置为霜剂、乳剂、悬浮剂、水剂、粉剂、面膜。
本申请提供的大麻提取物和青蒿提取物的组合,具有良好的抗氧化、防晒、缓解炎症反应或过敏反应以及抑制细菌生长的功效,并且其效果显著优于大麻提取物或青蒿提取物的单用效果,具有协同作用,取得了预料不到的技术效果。
具体实施方式
以下将结合实施例对本发明作进一步地说明,应理解这些实施例仅作为例证的目的,本发明可以通过许多不同形式的实施例来得以体现,本发明的保护范围并非仅限于文中提到的实施例。
实施例1:制备大麻和青蒿的提取物
大麻提取物:选取9-10月间大麻现蕾时花叶,自然晒干,或者鼓风烘箱50℃烘干至含水量低于10%。使用具塞三角瓶称取干叶100克,加入1升95%的乙醇,超声提取(上海之信超声发生器),设定提取功率为60K,温度60℃,提取30min,过滤分离提取液,真空浓缩干燥至无液体流出。
大麻二酚制备方法:将上述大麻提取物,用500ml氯仿溶解,用纯水萃取4次(每次75ml)。氯仿溶解部分(3g)用硅胶层析板层析,以含4%乙醇的氯仿展开,用大麻二酚标准品确定展开位置,刮下相应位置硅胶,氯仿溶解,加入20%的乙醇,结晶得到大麻二酚含量为95%以上。
青蒿提取物:选取9-10月间现蕾前的青蒿叶片,自然晒干,或者鼓风烘箱50℃烘干至含水量低于10%。使用具塞三角瓶称取干叶100克,加入1升95%的乙醇,超声提取(上海之信超声发生器),设定提取功率为60K,温度60度,提取30min,过滤分离提取液,真空浓缩干燥至无液体流出。
青蒿素制备方法:将上述青蒿提取物用石油醚溶解后,过硅胶柱吸附,用2倍柱体积的石油醚冲洗后,用石油醚:丙酮3:1的洗脱液洗脱,收集该部分洗脱液,真空干燥后,用乙醇溶解,结晶,可得到青蒿素含量为95%以上的青蒿素提取物。
实施例2:抗氧化活性检测
目前已建立的化学模型法有Trolox当量的抗氧化能力(trolox equivalentantioxidant capacity,TEAC)、1,1-二苯基-2-三硝基苯肼(DPPH)、总自由基捕获抗氧化参数(total radical-trapping antioxidant parameter,TRAP)和总氧自由基清除能力(total oxyradical scavenging capacity,TOSC)等方法。这些方法仅针对单一植物天然成分的理化特性(如水溶性或脂溶性)进行抗氧化能力测定,而且不采用容易被自由基氧化的脂类作为标准参照物,很难真实反映出植物天然活性成分的抗氧化活性。氧自由基吸收能力法(Oxygen radical absorbance capacity,ORAC)可以确定抗氧化物对偶氮二脒基丙烷盐酸盐(ABAP)产生的过氧化自由基的抑制清除效果,是一个经典的通过氢原子转移来清除由ABAP产生的ROO-、OH-等自由基的能力来评价抗氧化剂的抗氧化活性的方法,使用荧光指标剂的衰减曲线下面积(AUC)做为定量的手段。与其他抗氧化评价方法相比,该方法能够将抗氧化剂对自由基的抑制时间和抑制作用结合成一个单独的量。ORAC法是目前国际上常用的一种评价抗氧化剂活性的方法,现已成为美国农业部、美国国立卫生院、美国食品药品监督管理局(FDA)评价食品抗氧化能力的重要标准。美国、欧洲、日本等国家的食品、功能食品行业普遍采用ORAC作为功能食品的重要评价标准。
本实施例采用氧自由基清除测定法(ORAC),方法参照文献(余欣珂,明建,支玲,李苇舟,闫慧明,王启明,赵吉春.真空冷冻干燥对菊花多酚含量及其抗氧化活性的影响[J].食品与机械,2020,36(6):138-144.)对实施例1中所得的大麻提取物和青蒿提取物单独使用及其配方使用的抗氧化活性进行比较,结果见表1。
表1抗氧化活性
如表中所示,复方的抗氧化活性优于青蒿或大麻单独使用的效果,也优于2种的简单加和,具有协同增效作用。
实施例3青蒿大麻防晒霜感官及防晒指数评估
按照化妆品卫生规范标准测试防晒霜的感官评价。制取SPF15防晒霜基质和添加实施例1制备的2克大麻提取物和2克青蒿提取物的大麻青蒿防晒霜各100g,分别递交给专业的感官评价人员采用盲测方式对防晒霜总体感觉、吸收效果、涂展性、滋润效果、细腻性、光泽度、粘稠度、黏腻感、清爽度和拾取性作感官评价,每项评价实行打分制,9-10分为很好,7-8分为较好,5-6分为一般,3-4分为较差,1-2分为很差。结果见表2。
表2青蒿大麻防晒霜、防晒霜基质感官评分(n=10,x±s)
表中*表示与基质比较,得分具有显著差异。
结果表明青蒿和大麻提取物添加后不影响防晒霜的感官评价。
在48克的SPF15防晒霜基质中加入实施例1制备的1g大麻叶提取物或1g青蒿提取物或1g大麻青蒿提取物1:1混合物,制成防晒霜,分别用SPF-290仪测定三次SPF值和PA值,并用SPSS软件分析实验结果。结果见表3。
表3防晒指数结果
结果表明青蒿和大麻均有较好的防晒效果,且两者联用有协同增效的作用。
实施例4大麻及青蒿提取物活性成分抗炎抗过敏作用检测
使用实施例1中制备的大麻二酚和青蒿素验证其抗炎抗过敏作用。肥大细胞是由造血祖细胞衍化而来,广泛分布于结缔组织,皮肤上皮下方尤其多,其细胞较大,细胞质内含有嗜染性的粗大颗粒,当受到刺激,细胞内储存的媒介物质(组胺、肝素、Protease、加水分解酵素等)将被释放出来,参与多种免疫反应,包括炎症反应和过敏反应。炎症反应与肥大细胞脱颗粒密切相关,也是过敏反应过程中的关键步骤,抑制肥大细胞脱颗粒和释放组胺可减轻炎症反应的强度,因此可用以验证某种活性成分的抗炎和抗过敏的作用。结果见表4。
表4抗炎抗过敏结果
表4中,肥大细胞脱颗粒率(%)=(脱颗粒肥大细胞数/肥大细胞总数)×100;组胺释放率(%)=(组胺释放量/总的组胺释放量)×100;复方1:大麻二酚:青蒿素1:1;复方2:大麻二酚:青蒿素10:1;复方3:大麻二酚:青蒿素1:10;DMSO:二甲基亚砜;LPS:脂多糖。
结果表明青蒿素和大麻二酚均有较好的抗炎抗过敏效果,且两者以不同比例联用有协同增效的作用。
实施例5大麻及青蒿提取物活性成分抑菌作用检测
将灭菌固体LB培养基加热至熔化,待冷却至50℃时,每20ml培养基倒入无菌培养皿中。待平板自然晾干后,分别移取0.1ml待测药品(含20%的实施例1制备的大麻或青蒿提取物),0.1mL供试菌悬液(106个/ml),均匀涂布于加药平板上,每个处理3次重复,涂布30min后倒置。另设置对照组,涂菌,以等量无菌水(溶解药品物质)代替药液。上述操作在超净工作台内进行。将做好的细菌平板在37℃恒温培养24h,统计菌落个数,按照下式计算抑菌率。
结果表明,大麻青蒿提取物的组合物具有更好的抑菌效果。
实施例6组合物的制备
制备青蒿大麻组合物,大麻果实和青蒿叶片1:1混合,采用蒸馏法制备挥发油。
实施例7组合物的制备
制备青蒿大麻组合为,大麻叶片和青蒿叶片2:1混合,45度干燥2小时,超微粉碎后过300目筛。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术无需创造性劳动就可以根据本发明的构思作出诸多修改和变化。因此,凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到的技术方案,皆应在由权利要求书所确定的保护范围内。
Claims (10)
1.一种组合物,其特征在于,所述组合物包括大麻提取物和青蒿提取物,所述大麻提取物和青蒿提取物的比例为10:1至1:10。
2.如权利要求1所述的组合物,其特征在于,所述组合物具有至少如下功能之一:
a)抗氧化作用;
b)防御UVA和/或UVB对皮肤的损害;
c)缓解炎症反应或过敏反应;
d)抑制细菌生长。
3.如权利要求2所述的组合物,其特征在于,所述大麻提取物来自大麻花叶、大麻果仁、大麻籽油和/或大麻槿茎粉。
4.如权利要求2所述的组合物,其特征在于,所述青蒿提取物来自青蒿叶。
5.如权利要求3所述的组合物,其特征在于,所述大麻提取物为大麻二酚。
6.如权利要求4所述的组合物,其特征在于,所述青蒿提取物为青蒿素。
7.如权利要求3所述的,其特征在于,所述大麻提取物的制备方法为:选取9-10月大麻花叶,制成干制品,取所述干制品加入10倍重量的95%的乙醇,超声提取,分离提取液,真空浓缩干燥。
8.如权利要求4所述的组合物,其特征在于,所述青蒿提取物的制备方法为:选取9-10月青蒿叶,制成干制品,取所述干制品加入10倍重量的95%的乙醇,超声提取分离提取液,真空浓缩干燥。
9.如权利要求1所述的组合物,其特征在于,所述组合物的制备方法为:a)将大麻果实和青蒿叶片1:1混合,蒸馏法制备挥发油;或者,b)大麻叶片和青蒿叶片2:1混合,40℃-50℃干燥,超微粉碎后过300目筛。
10.权利要求1-9中任一项所述的组合物在制备护肤品或药品中的用途,所述护肤品或药品用于防晒、预防、缓解或治疗炎症反应、过敏性红斑和/或痤疮、抗菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011159114.2A CN112137935B (zh) | 2020-10-26 | 2020-10-26 | 一种组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011159114.2A CN112137935B (zh) | 2020-10-26 | 2020-10-26 | 一种组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112137935A true CN112137935A (zh) | 2020-12-29 |
CN112137935B CN112137935B (zh) | 2022-09-23 |
Family
ID=73953326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011159114.2A Active CN112137935B (zh) | 2020-10-26 | 2020-10-26 | 一种组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112137935B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106278828A (zh) * | 2016-08-16 | 2017-01-04 | 云南汉素生物科技有限公司 | 一种从工业大麻花叶中提取大麻二酚的方法 |
CN109646647A (zh) * | 2017-10-09 | 2019-04-19 | 徐广鑫 | 一种化淤酒 |
CN110063989A (zh) * | 2019-06-12 | 2019-07-30 | 栾云鹏 | 一种治疗食管癌的药物组合物及其制备方法 |
CN110403924A (zh) * | 2019-05-30 | 2019-11-05 | 栾云鹏 | 一种治疗皮肤黑色素瘤的药物组合物及其制备方法 |
-
2020
- 2020-10-26 CN CN202011159114.2A patent/CN112137935B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106278828A (zh) * | 2016-08-16 | 2017-01-04 | 云南汉素生物科技有限公司 | 一种从工业大麻花叶中提取大麻二酚的方法 |
CN109646647A (zh) * | 2017-10-09 | 2019-04-19 | 徐广鑫 | 一种化淤酒 |
CN110403924A (zh) * | 2019-05-30 | 2019-11-05 | 栾云鹏 | 一种治疗皮肤黑色素瘤的药物组合物及其制备方法 |
CN110063989A (zh) * | 2019-06-12 | 2019-07-30 | 栾云鹏 | 一种治疗食管癌的药物组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
潘文等: "《药园仙草:青蒿与青蒿素的前世今生》", 31 March 2016 * |
Also Published As
Publication number | Publication date |
---|---|
CN112137935B (zh) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101224697B1 (ko) | 테아세아 식물로부터의 생물활성 조성물 및 이들의 생산방법 및 용도 | |
MX2007005886A (es) | Composiciones farmaceuticas y terapeuticas derivadas de la planta garcinia mangostana l. | |
KR100982883B1 (ko) | 혼합추출물을 포함하는 화장료 조성물 및 이의 제조 방법 | |
WO2007002666A2 (en) | Pharmaceutical and therapeutic compostions derived from garcinia mangostana l plant | |
US20110151031A1 (en) | Compositions and methods for utilizing the same | |
CN113855620A (zh) | 含有天山雪莲细胞培养物的组合物及其制备方法与应用 | |
JPH07215884A (ja) | Tnf産生抑制作用を有するシソ抽出液 | |
Pardhi et al. | Anti-microbial, anti-oxidant and anthelmintic activity of crude extract of Solanum xanthocarpum | |
CN105726439A (zh) | 金蝉花美白保湿药妆品及其制备方法 | |
CN108938508B (zh) | 一种具有防晒增效作用的无花果果实提取物及其用途 | |
KR101901670B1 (ko) | 제주광나무 추출물을 유효성분으로 함유하는 안티폴루션 화장료 조성물 | |
CN105496842B (zh) | 一种肉苁蓉鳞茎提取物的制备方法及抗氧化作用 | |
CN112516031B (zh) | 一种植物萃取多效组合物及其制备方法 | |
CN110801412B (zh) | 一种皮脂仿生组合物及其应用和化妆品 | |
KR20150097336A (ko) | 개똥쑥으로부터 아토피 치료 및 예방 능을 갖는 유효성분 추출방법 및 그 방법으로 추출된 추출물과 그 추출물을 함유하는 아토피 치료 및 예방 능을 갖는 화장료 조성물 | |
Fatmawati et al. | Sunscreen Factor Formulation and Test of Gel Preparations of 70% Ethanol Extract on Arabica Coffee Leaf (Coffea arabica L.) | |
CN112137935B (zh) | 一种组合物及其用途 | |
KR102442714B1 (ko) | 중/원적외선 조사를 이용한 에키네시아 전초 추출물을 유효성분으로 함유하는 화장료 조성물 | |
WO2015186962A1 (ko) | 발효 녹차 추출물을 이용한 아토피성 피부염 개선용 조성물 | |
KR102654331B1 (ko) | 항 광노화, 진정 및 쿨링 효과를 가지는 발효 조성물 및 그 제조방법과 응용 | |
KR100712249B1 (ko) | 생약재 추출물을 함유하는 지성피부 개선용 화장료 조성물및 그 제조방법 | |
CN111265415B (zh) | 一种改性凹凸棒石及其制备方法和在外用药物和护肤品中的用途 | |
KR20110073947A (ko) | 쏘팔메토 추출물을 함유하는 화장료 조성물 및 그의 제조방법 | |
JP5465037B2 (ja) | 抗老化剤、抗酸化剤、美白剤、免疫賦活剤、皮膚外用剤および機能性経口組成物 | |
Tahir | Formulation Of Lipbalm From Sari Meat Papaya Fruit (Carica Papaya L.) As A Preparation Sunblock |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |